Reviewed by Michael Gill, B. Sc.
25 Cervical Cancer Clinical Trials Near Me
Top Hospitals for Cervical Cancer Clinical Trials
Image of M D Anderson Cancer Center in Texas.
M D Anderson Cancer Center
8Active Trials
32All Time Trials for Cervical Cancer
2005First Cervical Cancer Trial
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
6Active Trials
16All Time Trials for Cervical Cancer
1994First Cervical Cancer Trial
Top Cities for Cervical Cancer Clinical Trials
Cervical Cancer Clinical Trials by Phase of Trial
Phase < 1 Cervical Cancer Clinical Trials
6Active Cervical Cancer Clinical Trials
6Number of Unique Treatments
7Number of Active Locations
HB-201 ITProflavinePerflubutane Microbubble18F-FTXRadiation TherapyPositron Emission Tomography
Cervical Cancer Clinical Trials by Age Group
18+ Cervical Cancer Clinical Trials
84Active Cervical Cancer Clinical Trials
TelaglenastatKK-LC-1 TCR-T cellsSGN-ALPVPembrolizumab/Vibostolimab Co-FormulationRMC-5552SGN-STNVtrastuzumabHPV Self-Sampling
Top Treatments for Cervical Cancer Clinical Trials
Treatment Name
Active Cervical Cancer Clinical Trials
All Time Trials for Cervical Cancer
First Recorded Cervical Cancer Trial
Recently Completed Studies with FDA Approved Treatments for Cervical Cancer
Nagla Abdel Karim
tisotumab vedotin
Seagen Inc.
simlukafusp alfa
Hoffmann-La Roche
AGEN1884 + AGEN2034
Agenus Inc.
Agenus Inc.

What Are Cervical-Cancer Clinical Trials

Cervical cancer is when cells of the cervix adversely change. The cancer is typically a result of an infection with HPV (human papillomavirus). It is generally diagnosed after a Pap smear (Papanicolaou test).

Cervical cancer rarely produces symptoms at the early stages.

Cervical cancer is primarily either adenocarcinoma or squamous cell carcinoma (the most common).

In the 1970s, the HPV virus was detected by Dr. Harald zur Hausen, who went on to show that an HPV infection is related to cervical cancer. Clinical trials for cervical cancer primarily focus on treatments and early detection techniques.

Why Is Cervical-Cancer Being Studied Through Clinical Trials?

According to the CDC, cervical-cancer impacts 13,000 new people in the United States each year. The World Health Organization ranks it the fourth most common cancer in women, estimating that 570,000 women were diagnosed in 2018.

According to WHO, cervical cancers are some of the most treatable types of cancer, provided it is detected early. Thus, many clinical trials focus on improving early detection techniques. At present, Pap tests are the primary screening method. However, HPV DNA testing is also used. Some clinical trials are looking into new and improved HPV testing.

However, once cervical cancer has become persistent, treatments have traditionally only had a success rate of around 50%. Clinical trials are looking at ways to raise the percentage of positive outcomes.

Prevention of HPV infection is a crucial component of reducing cervical cancer. 2006 was the first time the FDA approved an HPV vaccine for teen girls and young women.

By 2021, 50% of the world was using an HPV vaccine, and many European countries had expanded their vaccination program to include boys. Consequently, the CDC has seen an 88% reduction in genital warts in teen girls and 81% in adult women, alluding to fewer HPV infections.

What Are The Types Of Treatments Available For Cervical-Cancer?

Cervical cancer is primarily treated by surgery when caught in the early stages. However, those diagnosed later often require chemotherapy and or radiation.

However, targeted treatments are emerging. 2021, tisotumab, an antibody drug, was approved by the FDA. 2021 was also when the KEYNOTE-826 trial published promising results for adding immunotherapy to treatment for patients with more advanced stages of cervical cancer.

Clinical trials for immunotherapy examine their safety, the percentage of improvement over chemotherapy alone, and if combining types of immunotherapies raises positive outcomes.

What Are Some Recent Breakthrough Clinical Trials For Cervical-Cancer?

2021: Immunotherapy, Pembrolizumab: Merck & Co funded the Phase 3 KEYNOTE-826 trial. It looked into using Keytruda (pembrolizumab) with chemotherapy as a treatment for patients with metastatic or recurrent cervical cancer. The double-blind trial involved 617 patients. The study showed positive outcomes went from 48%-50% to 66%.

2021: Immunotherapy, Balstilimab – Agenus Inc funded a study where researchers from various Gynecologic divisions, including James Comprehensive Cancer Center, Massey Cancer Center, and Oklahoma Cancer center, examined using balstilimab alone or with zalifrelimab, which work at different immune checkpoints. It is an approach that has been effectively used with other cancers.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 2nd, 2021

Last Reviewed: November 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003 Jun 21;361(9375):2099-106. Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, Rotmensch J, Barnes MN, Hanjani P, Leslie KK. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011 Jun 1;29(16):2259-65. doi: 10.1200/JCO.2010.32.6397. Epub 2011 May 2. Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, Manzuk L, Piha-Paul SA, Xu L, Zeigenfuss S, Pruitt SK, Leary A. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol. 2019 Jun 10;37(17):1470-1478. doi: 10.1200/JCO.18.01265. Epub 2019 Apr 3. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004 Dec;56(4):549-80. Review. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773. Vugmeyster Y, Grisic AM, Wilkins JJ, Loos AH, Hallwachs R, Osada M, Venkatakrishnan K, Khandelwal A. Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1. Cancer Chemother Pharmacol. 2022 Oct;90(4):369-379. doi: 10.1007/s00280-022-04468-6. Epub 2022 Sep 6. Tinker AV, Bhagat K, Swenerton KD, Hoskins PJ. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol. 2005 Jul;98(1):54-8. Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020 Oct 15;147(8):2190-2198. doi: 10.1002/ijc.33013. Epub 2020 May 2. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45. doi: 10.1200/JCO.2012.42.0505. Epub 2012 Apr 23. Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Mansfield A, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. J Clin Oncol. 2020 Jul 20;38(21):2407-2417. doi: 10.1200/JCO.19.02630. Epub 2020 May 28.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.